Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Stealth BioTherapeutics Inc. · Barth Syndrome
Phase 4
Recruiting
48
2026-07
Industry sponsor intelligence
Stealth BioTherapeutics Inc.Clinical Pipeline.
Lead-sponsor view of Stealth BioTherapeutics Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 27
- Recruiting
- 1
- Active
- 1
- Completed
- 20
- Results posted
- 13
- Avg enrollment
- 77
Pipeline overview
Programs by phase and activity.
Velocity
Stealth BioTherapeutics Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
31phase labels
Early Phase 10
Phase 112
Phase 214
Phase 34
Phase 41
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Elamipretide → | 27 | 12 | 14 | 4 | 1 | 2 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics Inc. · Age Related Macular Degeneration (ARMD)
Phase 3
Active, not recruiting
313
2026-05
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Stealth BioTherapeutics Inc. · Mitochondrial Myopathies · Mitochondrial Pathology
Phase 3
Completed
102
2025-10
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Stealth BioTherapeutics Inc. · Age-related Macular Degeneration
Phase 2
Completed
176
2024-07
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
Stealth BioTherapeutics Inc. · Barth Syndrome
Phase 2 / Phase 3
Completed
12
2024-04
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy
Stealth BioTherapeutics Inc. · Leber's Hereditary Optic Neuropathy
Phase 2
Completed
12
2021-11
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
Stealth BioTherapeutics Inc. · Fuchs' Corneal Endothelial Dystrophy (FCED)
Phase 1 / Phase 2
Completed
22
2021-09
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Stealth BioTherapeutics Inc. · Age-Related Macular Degeneration
Phase 1
Completed
40
2020-10
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
Stealth BioTherapeutics Inc. · Heart Failure
Phase 2
Completed
308
2020-07
Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
Stealth BioTherapeutics Inc. · Primary Mitochondrial Disease
Phase 2
Completed
30
2020-07
A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly
Stealth BioTherapeutics Inc. · Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Phase 2
Completed
41
2020-06
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
Stealth BioTherapeutics Inc. · Reperfusion Injury · STEMI
Phase 2
Completed
300
2020-06
Showing 10 of 20 studies
Search sponsor records
All Stealth BioTherapeutics Inc. studies.
This page groups studies where Stealth BioTherapeutics Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
27 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07531251Clinical Trial in Patients With Barth Syndrome- 4TAZPowerJul 13, 2026NCT06373731ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)May 20, 2026NCT05162768Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)Oct 24, 2025NCT04689360An Intermediate Size Expanded Access Protocol of ElamipretideFeb 14, 2025NCT03891875ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GAJul 12, 2024NCT03098797A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth SyndromeApr 16, 2024NCT03323749A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label ExtensionJan 24, 2022NCT02976038Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)Dec 17, 2021NCT02693119A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic NeuropathyNov 30, 2021NCT02653391A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)Sep 17, 2021